Anti-tumor selectivity of a novel Tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models
Author:
Publisher
Elsevier BV
Subject
Pharmacology,Biochemistry
Reference36 articles.
1. The concept of synthetic lethality in the context of anticancer therapy;Kaelin;Nat Rev Cancer,2005
2. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs;Schmidt;Drug Resist Update,2007
3. Molecular chaperone Hsp90 as a target for oxidant-based anticancer therapies;Beck;Curr Med Chem,2011
4. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent;Supko;Cancer Chemother Pharmacol,1995
5. The efficiency of multi-target drugs: the network approach might help drug design;Csermely;Trends Pharmacol Sci,2005
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects;Journal of Medicinal Chemistry;2024-09-10
2. The Potential Strategies for Overcoming Multidrug Resistance and Reducing Side Effects of Monomer Tubulin Inhibitors for Cancer Therapy;Current Medicinal Chemistry;2024-04
3. Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy;Bioorganic Chemistry;2023-10
4. Design, synthesis and development of a dual inhibitor of Topoisomerase 1 and poly (ADP-ribose) polymerase 1 for efficient killing of cancer cells;European Journal of Medicinal Chemistry;2023-10
5. Identification of Novel β-Tubulin Inhibitors Using a Combined In Silico/In Vitro Approach;Journal of Chemical Information and Modeling;2023-09-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3